Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 5:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 214 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cymbalta Clear all
Terminated Phase 2 Interventional Accepts healthy volunteers

Duloxetine Impact on Postoperative Pain Control and Outcomes

NCT05611749
View directory record Official record
Conditions
Acute Post-operative Pain, Chronic Post Operative Pain, Narcotic Use, Opioid Use, Opioid Addiction
Interventions
Duloxetine 60 MG, Placebo
Drug · Other
Lead sponsor
Scripps Health
Other
Eligibility
24 Years to 99 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 31, 2026, 5:09 AM EDT
Completed Phase 4 Interventional Results available

A Study of Duloxetine in Major Depressive Disorder (MDD) and Associated Painful Symptoms

NCT01000805
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
16
States / cities
Beverly Hills, California • Sherman Oaks, California • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2012 · Synced Oct 31, 2026, 5:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study of Duloxetine in the Reduction of Pain in Patient With Systemic Lupus Erythematosus

NCT01269866
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Cymbalta
Drug
Lead sponsor
Dr. Jesus Gutierrez Stone
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Oct 31, 2026, 5:09 AM EDT
Completed Phase 3 Interventional

A Study for the Treatment of Painful Diabetic Neuropathy

NCT00058968
View directory record Official record
Conditions
Diabetic Neuropathy, Painful
Interventions
Duloxetine hydrochloride, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Pembroke Pines, Florida
Source: ClinicalTrials.gov public record
Updated May 17, 2007 · Synced Oct 31, 2026, 5:09 AM EDT
Completed Phase 4 Interventional Results available

Duloxetine for Menopausal Depression

NCT01117857
View directory record Official record
Conditions
Depression, Menopause, Vasomotor Symptoms
Interventions
Duloxetine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Oct 31, 2026, 5:09 AM EDT
Active, not recruiting Phase 2 Interventional

Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy

NCT04560673
View directory record Official record
Conditions
Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Duloxetine, Neurofeedback, Quality-of-Life Assessment, Questionnaire Administration
Drug · Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 31, 2026, 5:09 AM EDT
Terminated Phase 3 Interventional Results available

SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study

NCT01436175
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SPD489 (Lisdexamfetamine dimesylate) + Antidepressant
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
140
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 113 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 31, 2026, 5:09 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder

NCT00384033
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Desvenlafaxine Succinate Sustained-Release (DVS SR), Placebo, Duloxetine 60 mg/day
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
638 participants
Timeline
2006 – 2007
U.S. locations
22
States / cities
Beverly Hills, California • Burbank, California • Encino, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 31, 2026, 5:09 AM EDT
Withdrawn Phase 4 Interventional

Effect of Preoperative Duloxetine on Quality of Recovery After Outpatient Laparoscopic Surgery

NCT02351440
View directory record Official record
Conditions
Quality of Recovery, Gynecologic Surgery, Laparoscopy
Interventions
duloxetine, placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Oct 31, 2026, 5:09 AM EDT
Completed Phase 4 Interventional Results available

Pain Response Evaluation of a Combined Intervention to Cope Effectively

NCT04395001
View directory record Official record
Conditions
Chronic Pain
Interventions
duloxetine, Web-based Cognitive Behavioral Therapy (CBT), Nurse-delivered Motivational Interviewing
Drug · Behavioral · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 65 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Oct 31, 2026, 5:09 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment

NCT02400346
View directory record Official record
Conditions
Major Depression Disorder
Interventions
Adjunct brexpiprazole, ADT
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
65 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
13
States / cities
Arcadia, California • Miami, Florida • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Oct 31, 2026, 5:09 AM EDT
Completed Phase 3 Interventional Results available

A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder

NCT04476030
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
SAGE-217, Matching Placebo, Sertraline, Escitalopram, Citalopram, Duloxetine, Desvenlafaxine
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 64 Years
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
51
States / cities
Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 42 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2023 · Synced Oct 31, 2026, 5:09 AM EDT
Completed Phase 2Phase 3 Interventional

Comparing Paroxetine and Duloxetine on Cardiovascular Measures

NCT00136383
View directory record Official record
Conditions
Depressive Symptoms
Interventions
paroxetine versus duloxetine
Drug
Lead sponsor
Duke University
Other
Eligibility
20 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Oct 31, 2026, 5:09 AM EDT
Completed Phase 4 Interventional

Safety and Effectiveness Study of Duloxetine HCl in Women of Different Backgrounds With Stress Urinary Incontinence Who May Also Have Other Various Medical Conditions.

NCT00190905
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
duloxetine HCl
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 25, 2006 · Synced Oct 31, 2026, 5:09 AM EDT
Not yet recruiting Phase 3 Interventional

An Artificial Intelligence Driven Approach to Optimize Patient Selection for a Transitional Pain Service

NCT07296770
View directory record Official record
Conditions
Postsurgical Pain Management, Postsurgical Pain, Chronic, Opioid Use After Surgery
Interventions
TPS-Select, Pharmacologic Pain Management, Interventional Pain Procedures, Psychological Management and Pain Education, Physical Therapy
Device · Drug · Procedure + 1 more
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 31, 2026, 5:09 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Cymbalta for Fibromyalgia Pain - Predictive Value of Small Fiber Changed

NCT01619566
View directory record Official record
Conditions
Fibromyalgia
Interventions
Duloxetine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 70 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 9, 2019 · Synced Oct 31, 2026, 5:09 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Antidepressant Medication Plus Donepezil for Treating Late-life Depression

NCT00177671
View directory record Official record
Conditions
Depression, Dementia
Interventions
Escitalopram, Donepezil, Venlafaxine, Placebo, Duloxetine
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
65 Years and older
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Oct 31, 2026, 5:09 AM EDT
Completed Phase 2 Interventional Results available

eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk

NCT04437485
View directory record Official record
Conditions
Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms, Type 2 Diabetes, PreDiabetes, Insulin Resistance
Interventions
Good Days Ahead (GDA), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications, Active Control
Behavioral · Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 31, 2026, 5:09 AM EDT
Completed Phase 3 Interventional Results available

A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder

NCT03538691
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Brexpiprazole, Antidepressant therapy
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Oct 31, 2026, 5:09 AM EDT
Terminated Phase 2 Interventional Results available

Research Examining Gulf War Illness in Our Nations Service Members

NCT01846182
View directory record Official record
Conditions
Gulf War Illness
Interventions
Duloxetine, Pregabalin, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
44 Years to 70 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Temple, Texas • Waco, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2021 · Synced Oct 31, 2026, 5:09 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Duloxetine Versus Placebo in Patients Taking a Nonsteroidal Anti-inflammatory Drug (NSAID) for Knee Pain Due to Osteoarthritis

NCT01018680
View directory record Official record
Conditions
Osteoarthritis Knee Pain
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
40 Years and older
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
32
States / cities
Tucson, Arizona • Garden Grove, California • Long Beach, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2012 · Synced Oct 31, 2026, 5:09 AM EDT
Completed Phase 2 Interventional Results available

eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients

NCT02458690
View directory record Official record
Conditions
Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms, Cardiovascular Diseases, Heart Diseases, Coronary Artery Disease, Stroke
Interventions
Beating the Blues (BtB), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications, Usual Care
Behavioral · Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
50 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 19, 2023 · Synced Oct 31, 2026, 5:09 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT03434041
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine 56 mg, Esketamine 84 mg, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
6
States / cities
Atlanta, Georgia • Shreveport, Louisiana • Gaithersburg, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 31, 2026, 5:09 AM EDT
Completed Not applicable Interventional Results available

Imaging Study of Chronic Low Back Pain in Patients Taking Pain Medication

NCT00388414
View directory record Official record
Conditions
Low Back Pain
Interventions
duloxetine, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 60 Years · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Oct 31, 2026, 5:09 AM EDT